Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-06-24
2008-06-24
Henley, III, Raymond J (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07390830
ABSTRACT:
This invention provides remedies or prophylactics for diseases in association with chemokines such as MIP-1 α and/or MCP-1. Namely, remedies or prophylactics for diseases in association with the chemokines such as rheumatoid arthritis or nephritis contain, as the active ingredient, cyclic amine derivatives represented by the following formula (I), pharmaceutically acceptable acid addition salts thereof or pharmaceutically acceptable C1-C6alkyl addition salts thereof.
REFERENCES:
patent: 4443461 (1984-04-01), Ward
patent: 6166015 (2000-12-01), Rogers et al.
patent: 6362177 (2002-03-01), Shiota et al.
patent: 6410566 (2002-06-01), Shiota et al.
patent: 6451842 (2002-09-01), Shiota et al.
patent: 13825/00 (2000-06-01), None
patent: 47967/00 (2000-12-01), None
patent: 1279668 (2001-01-01), None
patent: 217286 (1987-04-01), None
patent: 217286 (1987-04-01), None
patent: 903349 (1999-03-01), None
patent: 1 201 239 (2002-05-01), None
patent: 841 081 (1984-09-01), None
patent: 2106108 (1983-04-01), None
patent: WO 97/24325 (1997-07-01), None
patent: WO 97/40051 (1997-10-01), None
patent: WO 97/44329 (1997-11-01), None
patent: WO 98/02151 (1998-01-01), None
patent: WO 98/04554 (1998-02-01), None
patent: WO 98/06703 (1998-02-01), None
patent: WO 98/25604 (1998-06-01), None
patent: WO 98/25605 (1998-06-01), None
patent: WO 98/25617 (1998-06-01), None
patent: WO 98/27815 (1998-07-01), None
patent: WO 98/30218 (1998-07-01), None
patent: WO 98/31364 (1998-07-01), None
patent: WO 98/38167 (1998-09-01), None
patent: 98/50534 (1998-11-01), None
patent: WO 98/50534 (1998-11-01), None
patent: WO 98/50534 (1998-11-01), None
patent: WO 99/01127 (1999-01-01), None
patent: 99/25686 (1999-05-01), None
patent: WO 99/25686 (1999-05-01), None
patent: WO 00/9377 (2000-02-01), None
patent: 00/31032 (2000-06-01), None
patent: WO 00/31032 (2000-06-01), None
patent: WO 00/31033 (2000-06-01), None
patent: WO 00/35449 (2000-06-01), None
patent: WO 00/35451 (2000-06-01), None
patent: WO 00/69815 (2000-11-01), None
patent: WO 69815 (2000-11-01), None
Webster's II, New Riverside University Dictionary, 1988, pp. 944 and 933.
Merck Manual of Diagnosis and Therapy, 17th Edition, 1999, pp. 416-423, 1473-1476, and 1864-1869.
Khalid, M. et al., “N,N'—disubstituted L-isoglutamines as novel cancer chemotherapeutic agents”, Drugs Exp. Clin. Res., vol. 13, Suppl.1, pp. 57-60 (1987).
Krishna Vaddi, “Chemokine Facts Book, Acad. Press,” 1997 San Diego, CA.
Franklin H. Epstein, M.D., Luster, D. Andrew, “Chemokines—Chemotactic Cytokines that Mediate Inflammation”, The New England Journal of Medicine (Feb. 12, 1998), vol. 338 pp. 436-445.
Marco Baggiolini “Chemokines and leukocyte traffic” NATURE vol. 392 pp. 565-568 Apr. 9, 1998.
Joseph Hesselgesser “Identification and Characterization of Small Molecule Functional Antagonists of the CCR1 Chemokine Receptor” The Journal of Biological Chemistry vol. 273, No. 25, Jun. 19, 1998 pp. 15687-15692.
European Communication Nov. 29, 2002.
Khalid, M. Burzynski S.R. et al., “N,N'—disubstituted L-isoglutamines as novel cancer chemotherapeutic agents”, Drugs Exp. Clin. Res., vol. 13, Suppl. 1, pp. 57-60 (1987).
Bright, Colin, et al. Identification of a Non- Peptidic Rantes Antagonist, vol. 1, No. 1, Bioorganic & Medicinal Chemistry Letters, 1998 pp. 771-774.
Howard, O.M.Z., et al. Inhibition of in Vitro and in Vivo HIV Replication by a Distamycin Analogue that Interferes with Chemokin Receptor Function : A Candidate for Chemotherapeutic and Microbicidal Application, J. Med. Chem. 1998, 41, No. 13, pp. 2184-2193.
Ward, G. Stephen, et al., “Chemokines: understanding their role in T-lymphocyte biology”, Biochem. J. (1998) 333, 457-470.
European Communication Sep. 17, 2003.
Rapport, Carol A., et al., “Molecular Cloning and Functional Characterization of a Novel Human CC Chemokine Receptor (CCR5) for Rantes, MIP-1β, and MIP-1α,” The Journal of Biological Chemistry, The American Society for Biochemistry and Molecular Biology, Inc., 1996, pp. 17161-17166, vol. 271, No. 29, Issue of July 19th, USA.
Murai, Masako, et al., “Active participation of CCR5+CD8+T lymphocytes in the pathogenesis of liver injury in graft-versus-host disease,” The Journal of Clinical Investigations, Jul. 1999, pp. 49-57, vol. 104, No. 1.
Balashov, Konstantin E., “CCR5+and CXCR3+T cells are Increased in multiple sclerosis and their ligands MIP-1α and IP-10 are expressed in demyelinating brain lesions,” Proc. Natl. Acad. Sci., Jun. 1999, pp. 6873-6878, vol. 90, USA.
Bradley, Linda, et al., The Journal of Immunology, vol. 162(5), pp. 2511-2520, Mar. 4, 1999.
N. Zimmerman, et al. “Polymorphisms in the human CC chemokine receptor-3 gene”Biochimica et Biophysica Acta. Gene Structure and Expression, Elsevier, Amsterdam, NL, vol. 1442, No. 2-3, Nov. 8, 1998, pp. 170-176, XP004275252.
H. Choe, et al. “The Beta-Chemokine Receptors CCR3 and CCR5 Facilitate Infection by Primary HIV-1 Isolates”Cell, Cell Press, Cambridge MA, US, vol. 85, No. 7, Jun. 28, 1996, pp. 1135-1148, XP002061250.
Chen, et al. “CCR3 and CCR5 are co-receptors for HIV-infection of microglia”Nature, Macmillan Journals Ltd., London, GB, vol. 385, No. 6617, Feb. 13, 1997, pp. 645-649, XP002107165.
Canella, Barbara; Hoban, Carolyn J.; Gao, Yan-ling; Garcia-Arenas, Renee; Lawson, Deborah; Marchionni, Mark; Gwynne, David; Raine, Cedric S., “The neuregulin, glial growth factor 2, diminishes autoimmune demyelination and enhances remyelination in a chronic relapsing model for multiple sclerosis”; Proceedings of the National Academy of Sciences, Aug. 1998, pp. 10100-10105, vol. 95, USA.
Tran, Elise H.; Hoekstra, Karin; van Rooijen, Nico; Dijkstra, Christine D.; Owens, Trevor, “Immune Invasion of the Central Nervous System Parenchyma and Experimental Allergic Encephalomyelitis, But Not Leukocyte Extravasation from Blood, Are Prevented in Macrophage-Depleted Mice,” The Journal of Immunology, 1998, pp. 3767-3775, vol. 161, U.S.A.
Butterfield, Russell J.; Sudweeks, Jayce D.; Blankenhorn, Elizabeth P.; Korngold, Robert; Marini, Joseph C.; Todd, John A.; Roper, Randall J.; Teuscher, Cory, “New Genetic Loci That Control Susceptability and Symptoms of Experimental Allergic Encephalomyelitis in Inbred Mice,” The Journal of Immunology, 1998, pp. 1860-1867, vol. 161, U.S.A.
Karpus, William J.; Ransohoff, Richard M., “Cutting Edge Commentary: Chemokine Regulation of Experimental Autoimmune Encephalomyelitis: Temporal and Spatial Expression Patterns Govern Disease Pathogenesis,” The Journal of Immunology, 1998, pp. 2667-2671, vol. 161, U.S.A.
Rajan, Alice J.; Klien, Jonathan D.S.; Brosnan, Celia F., “The Effect of yō T Cell Depletion on Cytokine Gene Expression in Experimental Allergic Encephalomyelitis,” The Journal of Immunology, 1998, pp. 5955-5962, vol. 160, U.S.A.
Horiuchi Hideki
Kamimura Takashi
Miyagi Fuminori
Ohta Tomohiro
Shiota Tatsuki
Henley, III Raymond J
Sughrue & Mion, PLLC
Teijin Limited
LandOfFree
Remedies or prophylactics for diseases in association with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Remedies or prophylactics for diseases in association with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Remedies or prophylactics for diseases in association with... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2798598